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Introduction {#jah31145-sec-0004}
============

Stroke outcomes are worse in patients with diabetes.[1](#jah31145-bib-0001){ref-type="ref"}, [2](#jah31145-bib-0002){ref-type="ref"} This is likely due to hyperglycemia, which is considered a poor prognostic factor in stroke patients.[3](#jah31145-bib-0003){ref-type="ref"}, [4](#jah31145-bib-0004){ref-type="ref"} Increased admission glucose levels in acute stroke have also been associated with longer in‐hospital stay, increased cost, and mortality.[5](#jah31145-bib-0005){ref-type="ref"} Hyperglycemia before reperfusion potentially decreases the beneficial effect of tissue‐type plasminogen activator (tPA)[6](#jah31145-bib-0006){ref-type="ref"} given that hyperglycemia may act as an inhibitor of fibrinolysis.[7](#jah31145-bib-0007){ref-type="ref"}

Some studies have reported an increased risk of symptomatic intracranial hemorrhage (sICH) after tPA treatment in patients with diabetes or hyperglycemia,[8](#jah31145-bib-0008){ref-type="ref"}, [9](#jah31145-bib-0009){ref-type="ref"}, [10](#jah31145-bib-0010){ref-type="ref"} and admission glucose has been used in prognostic models to identify patients at risk of sICH after tPA.[11](#jah31145-bib-0011){ref-type="ref"} Even though studies did not find overall reduced benefit of tPA in diabetic patients,[12](#jah31145-bib-0012){ref-type="ref"} decreased rates of tPA administrations are observed in diabetic patients.[13](#jah31145-bib-0013){ref-type="ref"} Guidelines recommend against tPA use in the 3‐ to 4.5‐hour window in patients with prior stroke plus diabetes based on insufficient evidence for its effectiveness, as patients with both prior stroke and diabetes were excluded from the European Cooperative Acute Stroke Study 3 trial.[14](#jah31145-bib-0014){ref-type="ref"} In this study, we sought to evaluate the relationship between admission hyperglycemia and the chronic hyperglycemic state on clinical outcomes in acute ischemic stroke patients with and without a recognized history of diabetes who were treated with tPA.

Methods {#jah31145-sec-0005}
=======

We identified 87 975 AIS patients from 1586 sites that received intravenous tPA from 2009 to 2013 using the Get With The Guidelines Stroke (GWTG‐Stroke) database. Details of the GWTG‐Stroke program, including the methods of data collection and data definitions used, have been described previously.[15](#jah31145-bib-0015){ref-type="ref"}, [16](#jah31145-bib-0016){ref-type="ref"}, [17](#jah31145-bib-0017){ref-type="ref"}, [18](#jah31145-bib-0018){ref-type="ref"} All participating institutions were required to comply with local regulatory and privacy guidelines and, if required, to secure institutional review board (IRB) approval. Because data were used primarily at the local site for quality improvement, sites were granted a waiver of informed consent under the common rule. Quintiles (Cambridge, MA) served as the registry coordinating center for the American Heart Association/American Stroke Association Get With The Guidelines programs. The Duke Clinical Research Institute (Durham, NC) served as the data analysis center, and IRB approval was granted to analyze aggregate deidentified data for research purposes. We excluded 3843 patients because of missing documentation on the National Institutes of Health Stroke Scale (NIHSS), and 11 223 patients discharged or transferred to another acute care facility left against medical advice or discharge destination not documented. Of the remaining 72 909 patients, admission glucose was not documented for 14 644 patients. The final cohort consisted of 58 265 AIS patients treated with tPA. Because abnormal glucose metabolism might exert its effects by several different mechanisms, either through chronic injury resulting from diabetes or acute injury through hyperglycemia, we classified patients based on either laboratory findings or clinical history. Random plasma glucose measured at admission identified subjects with or without acute hyperglycemia. Chronic hyperglycemia was manifest as either a known previous diagnosis of diabetes mellitus (DM) in some patients, whereas others presented with occult diabetes diagnosed during the index stroke admission by elevated levels of glycosylated hemoglobin (HbA1c). The two types of hyperglycemia were defined using the latest American Diabetes Association criteria: Acute hyperglycemia at admission was defined as a random plasma glucose level \>140 mg/dL, and chronic hyperglycemia was defined as a plasma level of HbA1c \>6.5%.[19](#jah31145-bib-0019){ref-type="ref"}

Statistical Analysis {#jah31145-sec-0006}
--------------------

Contingency tables were generated to explore the relationship between important covariates, including demographics, clinical variables, medical history, and hospital‐level characteristics, by presence of acute hyperglycemia in AIS patients treated with tPA. Primary outcomes of interest were complications of tPA thrombolytic therapy (symptomatic hemorrhage \[sICH\] and life‐threatening systemic hemorrhage) and all‐cause in‐hospital mortality. Other outcomes of interest were length of stay and ambulatory status at discharge. Chi‐square for categorical variables or Wilcoxon test for continuous data were used as tests for statistical associations.

Outcomes among stroke patients receiving tPA were compared between acute hyperglycemic and nonhyperglycemic patients using logistic regression with generalized estimating equations to account for within‐site clustering. Each outcome was modeled using a tiered approach. First, the unadjusted odds ratios were calculated. Next, patient characteristics were added to the model (age, gender, race \[white vs other\], medical history of atrial fib/flutter, previous stroke/transient ischemic attack \[TIA\], coronary artery disease \[CAD\]/previous myocardial infarction \[MI\], carotid stenosis, DM, peripheral vascular disease \[PVD\], hypertension, dyslipidemia, smoking, and NIHSS). Finally, hospital characteristics (region, academic/teaching hospital, number of beds, rural location, TJC primary stroke center status, annual ischemic stroke volume, and annual tPA volume) were added to the model. Blood glucose and HbA1c were not included in the multivariable models. Single imputations were used to reduce missingness in the models. Blood glucose and HbA1c as continuous variables were modeled with linear splines to analyze relationships with outcomes of in‐hospital mortality and sICH. A knot point of 200 mg/dL provided the best fit. There was no evidence of further association above blood glucose 200 mg/dL. Next, blood glucose was modeled from 40 to 200 mg/dL with a linear spline. HbA1c was modeled from 0% to 20%.

Analyses were also performed in 2 important subgroups: (1) patients with chronic hyperglycemia as determined solely by HbA1c values and (2) patients with a documented history of DM and available hyperglycemia laboratory values. For each outcome, interaction between patients with documented history of diabetes versus no diabetes in relation to acute hyperglycemia or HbA1c were analyzed, where an interaction test *P*\<0.05 would suggest evidence of a significant interaction between diabetic and nondiabetic patients in relation to acute hyperglycemia or HbA1c and outcomes.

Laboratory data on admission were not recorded in a large number of subjects for plasma glucose (n=14 644; 20.1%) and HbA1c (n=26 760; 36.7%). In order to determine whether this missingness was nonrandom, we compared patients characteristics between those with versus without a recorded admission glucose and those with versus without a recorded HbA1c (Tables S1 and S2).

Results {#jah31145-sec-0007}
=======

There were 72 909 patients available for analysis overall. Over the entire cohort, median age was 72 years (interquartile range \[IQR\], 59 to 82), 50.3% were female, and median NIHSS was 10 (6 to 17). Admission glucose was available for 58 265 and HbA1c for 31 505 patients. Median blood glucose level was 119 mg/dL (IQR, 102 to 148), and median HbA1c was 5.9% (IQR, 5.5 to 6.6). The distribution of recorded blood glucose and HbA1c values are shown in Figures [1](#jah31145-fig-0001){ref-type="fig"} and [2](#jah31145-fig-0002){ref-type="fig"}, respectively. A previous history of diabetes was documented in 15 232 patients; of these with history of diabetes, 9363 had blood glucose \>140 mg/dL at admission and 6346 had HbA1c \>6.5.

![Distribution of admission blood glucose (BG) values.](JAH3-4-e002193-g001){#jah31145-fig-0001}

![Distribution of glycosylated hemoglobin (HbA1c) values.](JAH3-4-e002193-g002){#jah31145-fig-0002}

Acute Hyperglycemia on Admission {#jah31145-sec-0008}
--------------------------------

Characteristics of AIS patients treated with intravenous tPA according to admission blood glucose level are presented in Table [1](#jah31145-tbl-0001){ref-type="table-wrap"}. When compared to patients with no acute hyperglycemia, those with acute hyperglycemia (n=17 203) were older in age, more frequently males, and had higher median stroke severity as measured by NIHSS. They had longer median onset to treatment time and had more frequently documented medical history of CAD, DM, PVD, hypertension, carotid stenosis, dyslipidemia, and heart failure and were more likely to be smokers. There were higher rates of sICH (6.2% vs 4.0%; *P*\<0.0001), life‐threatening hemorrhage (1.6% vs 0.8%; *P*\<0.0001), and in‐hospital mortality (11.3% vs 6.4%; *P*\<0.0001) in patients with acute hyperglycemia when compared to no hyperglycemia (Table [1](#jah31145-tbl-0001){ref-type="table-wrap"}). Almost one third of patients with hyperglycemia that survived in hospital were unable to ambulate independently at discharge.

###### 

Baseline Patient Characteristics of Acute Stroke Patients With vs Without Acute Hyperglycemia

  Variable                                Level    Overall (N=58 265)   Acute Hyperglycemia (BG \>140 mg/dL) (N=17 203)   No Acute Hyperglycemia (BG ≤140 mg/dL) (N=41 062)   *P* Value                    
  --------------------------------------- -------- -------------------- ------------------------------------------------- --------------------------------------------------- ----------- -------- ------- ----------
  Age                                     Median   58 265               72.0                                              17 203                                              72.0        41 062   71.0    0.0001
  25th                                             59.0                                                                   61.0                                                            59.0             
  75th                                             82.0                                                                   81.0                                                            82.0             
  Sex                                     Female   29 306               50.30                                             8465                                                49.2        20 841   50.8    0.0006
  Onset to treatment time (minutes)       Median   55 869               141.0                                             16 463                                              145.0       39 406   140.0   \<0.0001
  25th                                             110.0                                                                  112.0                                                           109.0            
  75th                                             175.0                                                                  175.0                                                           174.0            
  Medical history                                                                                                                                                                                          
  CAD/previous MI                                  14 588               25.1                                              4999                                                29.1        9589     23.4    \<0.0001
  Carotid stenosis                                 1548                 2.7                                               528                                                 3.1         1020     2.5     \<0.0001
  Diabetes mellitus                                15 232               26.2                                              9363                                                54.5        5869     14.3    \<0.0001
  PVD                                              2058                 3.5                                               736                                                 4.3         1322     3.2     \<0.0001
  Hypertension                                     42 660               73.3                                              13 763                                              80.1        28 897   70.4    \<0.0001
  Smoker                                           10 605               18.2                                              2614                                                15.2        7991     19.5    \<0.0001
  Dyslipidemia                                     23 907               41.1                                              7720                                                44.9        16 187   39.4    \<0.0001
  Heart failure                                    5330                 9.2                                               1905                                                11.1        3425     8.4     \<0.0001
  NIHSS Score                             Median   58 265               10.0                                              17 203                                              11.0        41 062   10.0    \<0.0001
  25th                                             6.0                                                                    6.0                                                             6.0              
  75th                                             17.0                                                                   18.0                                                            17.0             
  HbA1C, %                                Median   31 505               5.9                                               10 626                                              6.8         20 879   5.8     \<0.0001
  25th                                             5.5                                                                    6.0                                                             5.4              
  75th                                             6.6                                                                    8.3                                                             6.1              
  Complications of thrombolytic therapy                                                                                                                                                                    
  Symptomatic ICH                                  2717                 4.7                                               1067                                                6.2         1650     4.0     \<0.0001
  Serious/life‐threatening hemorrhage              594                  1.0                                               279                                                 1.6         315      0.8     \<0.0001
  Other complication                               1968                 3.4                                               717                                                 4.2         1251     3.1     \<0.0001
  Other outcomes                                                                                                                                                                                           
  In‐hospital mortality                            4572                 7.9                                               1937                                                11.3        2635     6.4     \<0.0001
  LOS \>4 days                                     29 026               51.4                                              9435                                                56.5        19 591   49.3    \<0.0001
  Unable to ambulate at discharge                  15 112               29.0                                              5616                                                36.5        9496     25.9    \<0.0001
  Hospital characteristics                                                                                                                                                                                 
  Academic/teaching hospital                       36 909               63.7                                              10 953                                              64.0        25 956   63.6    0.36
  Region                                  West     11 517               19.8                                              3306                                                19.2        8211     20.0    0.0002
  South                                   20 743   35.6                 6128                                              35.6                                                14 615      35.6             
  Midwest                                 11 300   19.4                 3237                                              18.8                                                8063        19.6             
  Northeast                               14 705   25.2                 4532                                              26.3                                                10 173      24.8             

BG indicates blood glucose; CAD, coronary artery disease; HbA1c, glycosylated hemoglobin; ICH, intracranial hemorrhage; LOS, length of stay; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; PVD, peripheral vascular disease.

In multivariable analyses, fully adjusting for patient and hospital characteristics, blood glucose \>140 mg/dL was independently associated with sICH (adjusted odds ratio \[aOR\], 1.41; 95% confidence interval \[CI\], 1.29 to 1.53), life‐threatening hemorrhage (aOR, 2.13; 95% CI, 1.82 to 2.49), in‐patient mortality (aOR, 1.68; 95% CI, 1.57 to 1.8), length of stay \>4 days (aOR, 1.17; 95% CI, 1.12 to 1.22), and inability to ambulate at discharge (aOR, 1.51; 95% CI, 1.44 to 1.59) (Table [2](#jah31145-tbl-0002){ref-type="table-wrap"}).

###### 

Multivariable Model of the Association Between Acute Hyperglycemia[a](#jah31145-note-0004){ref-type="fn"} and Clinical Outcomes

  Outcome                                 Unadjusted Model   Adjusted Model (Patient Characteristics)   Fully Adjusted Model (Patient and Hospital Characteristics)                                                          
  --------------------------------------- ------------------ ------------------------------------------ ------------------------------------------------------------- ------ -------------- ---------- ------ -------------- ----------
  Complications of thrombolytic therapy                                                                                                                                                                                      
  Symptomatic ICH                         1.57               (1.45, 1.69)                               \<0.0001                                                      1.40   (1.29, 1.53)   \<0.0001   1.41   (1.29, 1.53)   \<0.0001
  Serious/life‐threatening hemorrhage     2.13               (1.82, 2.49)                               \<0.0001                                                      1.90   (1.61, 2.25)   \<0.0001   2.13   (1.82, 2.49)   \<0.0001
  Other complication                      1.38               (1.26, 1.52)                               \<0.0001                                                      1.24   (1.12, 1.38)   \<0.0001   1.25   (1.12, 1.39)   \<0.0001
  Other outcomes                                                                                                                                                                                                             
  In‐hospital mortality                   1.87               (1.76, 1.98)                               \<0.0001                                                      1.69   (1.58, 1.82)   \<0.0001   1.68   (1.57, 1.80)   \<0.0001
  LOS \>4                                 1.31               (1.27, 1.36)                               \<0.0001                                                      1.17   (1.12, 1.22)   \<0.0001   1.17   (1.12, 1.22)   \<0.0001
  Unable to ambulate at discharge         1.65               (1.58, 1.72)                               \<0.0001                                                      1.52   (1.45, 1.59)   \<0.0001   1.51   (1.44, 1.59)   \<0.0001

Variables used for patient characteristics: age, gender, race (white vs other), medical history of atrial fib/flutter, previous stroke/TIA, CAD/previous MI, carotid stenosis, diabetes, PVD, hypertension, dyslipidemia, smoking, presentation during off hours, NIHSS, and systolic blood pressure. For hospital characteristics: region, academic/teaching hospital, number of beds, rural location, TJC primary stroke center status, annual ischemic stroke volume, and annual tPA volume. BG indicates blood glucose; CAD, coronary artery disease; CI, confidence interval; ICH, intracranial hemorrhage; LOS, length of stay; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; PVD, peripheral vascular disease; TIA, transient ischemic attack; TJC, the joint commission; tPA, tissue plasminogen activator.

Acute hyperglycemia defined as BG \>140 mg/dL.

Chronic Hyperglycemia by HbA1c {#jah31145-sec-0009}
------------------------------

HbA1C was documented in 31 505 AIS patients treated with tPA. When compared to patients with HbA1c ≤6.5%, patients with elevated HbA1c were younger in age, more frequently male, and had a longer median onset to tPA treatment time. They had more‐frequent documented history of CAD, DM, hypertension, PVD, dyslipidemia, and heart failure (Table [3](#jah31145-tbl-0003){ref-type="table-wrap"}). Patients with elevated HbA1c had higher rates of post‐tPA complications, in‐patient mortality, and increased length of stay and were less likely to ambulate at discharge. After adjustment for patient and hospital characteristics, patients with HbA1c of \>6.5%, compared to those with ≤6.5%, was independently associated with sICH (aOR, 1.25; 95% CI, 1.07 to 1.46), life‐threatening hemorrhage (aOR, 1.34; 95% CI, 1.05 to 1.72), in‐patient mortality (OR, 1.36; 95% CI, 1.21 to 1.53), length of stay \>4 days (aOR, 1.21; 95% CI, 1.13 to 1.3), and inability to ambulate at discharge (aOR, 1.29; 95% CI, 1.19 to 1.39; Table [4](#jah31145-tbl-0004){ref-type="table-wrap"}).

###### 

Baseline Patient Characteristics of Acute Stroke Patients With vs Without Chronic Hyperglycemia as Measured by HbA1C Levels

  Variable                                Level    Overall (N=31 505)   HbA1C \>6.5% (N=8060)   HbA1C ≤6.5% (N=23 445)   *P* Value                    
  --------------------------------------- -------- -------------------- ----------------------- ------------------------ ----------- -------- ------- ----------
  Patient characteristics                                                                                                                             
  Age                                     Median   31 505               70.0                    8060                     68.0        23 445   71.0    \<0.0001
  25th                                             58.0                                         58.0                                 58.0             
  75th                                             81.0                                         78.0                                 82.0             
  Mean                                             68.9                                         67.7                                 69.3             
  Gender                                  Female   15 344               48.7                    3689                     45.8        11 655   49.7    \<0.0001
  Onset to treatment time (minutes)       Median   30 222               141.0                   7710                     145.0       22 512   140.0   \<0.0001
  25th                                             110.0                                        114.0                                108.0            
  75th                                             175.0                                        177.0                                174.0            
  Medical history                                                                                                                                     
  Atrial fibrillation/flutter                      6329                 20.1                    1407                     17.5        4922     21.0    \<0.0001
  Previous stroke/TIA                              7632                 24.2                    2128                     26.4        5504     23.5    \<0.0001
  CAD/previous MI                                  7954                 25.3                    2588                     32.1        5366     22.9    \<0.0001
  Carotid stenosis                                 829                  2.6                     244                      3.0         585      2.5     0.01
  Diabetes mellitus                                9954                 31.6                    6346                     78.8        3608     15.4    \<0.0001
  PVD                                              1102                 3.5                     376                      4.7         726      3.1     \<0.0001
  Hypertension                                     23 450               74.5                    6701                     83.2        16 749   71.5    \<0.0001
  Smoker                                           6103                 19.4                    1377                     17.1        4726     20.2    \<0.0001
  Dyslipidemia                                     13 034               41.4                    3961                     49.8        9073     38.7    \<0.0001
  Heart failure                                    2913                 9.3                     911                      11.3        2002     8.5     \<0.0001
  NIHSS Score                             Median   31 505               10.0                    8060                     10.0        23 445   10.0    \<0.0001
  25th                                             6.0                                          6.0                                  6.0              
  75th                                             17.0                                         16.0                                 17.0             
  Mean                                             11.7                                         11.4                                 11.8             
  Blood glucose, mg/dL                    Median   31 505               122.0                   8060                     183.0       23 445   114.0   \<0.0001
  25th                                             104.0                                        140.0                                100.0            
  75th                                             156.0                                        250.0                                134.00           
  Complications of thrombolytic therapy                                                                                                               
  Symptomatic ICH                                  1379                 4.4                     405                      5.1         974      4.2     0.001
  Serious/life‐threatening hemorrhage              271                  0.9                     85                       1.1         186      0.8     0.02
  Other complication                               1011                 3.2                     291                      3.6         720      3.1     0.02
  Other outcomes                                                                                                                                      
  In‐hospital mortality                            2145                 6.8                     639                      7.9         1506     6.4     \<0.0001
  LOS \>4 days                                     16 071               52.8                    4438                     57.2        11 633   51.3    \<0.0001
  Unable to ambulate at discharge                  8064                 27.5                    2265                     30.3        5799     26.5    \<0.0001
  Hospital characteristics                                                                                                                            
  Academic/Teaching Hospital                       21 144               67.4                    5301                     66.1        15 843   67.9    0.003
  Region                                  West     6336                 20.1                    1530                     18.9        4806     20.5    0.02
  South                                   11 360   36.1                 2958                    36.7                     8402        35.8             
  Midwest                                 6186     19.6                 1566                    19.4                     4620        19.7             
  Northeast                               7623     24.2                 2006                    24.9                     5617        23.9             

CAD indicates coronary artery disease; HbA1c, glycosylated hemoglobin; ICH, intracranial hemorrhage; LOS, length of stay; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; PVD, peripheral vascular disease; TIA, transient ischemic attack.

###### 

Multivariable Model of the Association Between Chronic Hyperglycemia[a](#jah31145-note-0007){ref-type="fn"} and Clinical Outcomes

  Outcome                                 Unadjusted Model   Adjusted Model (Patient Characteristics Only)   Adjusted Model (Patient and Hospital Characteristics)                                                          
  --------------------------------------- ------------------ ----------------------------------------------- ------------------------------------------------------- ------ -------------- ---------- ------ -------------- ----------
  Complications of thrombolytic therapy                                                                                                                                                                                     
  Symptomatic ICH                         1.22               (1.08, 1.38)                                    0.002                                                   1.24   (1.06, 1.45)   0.01       1.25   (1.07, 1.46)   0.01
  Serious/life‐threatening hemorrhage     1.34               (1.05, 1.72)                                    0.02                                                    1.37   (0.99, 1.89)   0.07       1.34   (1.05, 1.72)   0.02
  Other complication                      1.18               (1.04, 1.35)                                    0.01                                                    1.05   (0.89, 1.24)   0.57       1.06   (0.89, 1.25)   0.52
  Other outcomes                                                                                                                                                                                                            
  In‐hospital mortality                   1.28               (1.17, 1.40)                                    \<0.0001                                                1.37   (1.21, 1.54)   \<0.0001   1.36   (1.21, 1.53)   \<0.0001
  LOS \>4                                 1.26               (1.20 1.3)                                      \<0.0001                                                1.21   (1.13, 1.30)   \<0.0001   1.21   (1.13, 1.30)   \<0.0001
  Unable to ambulate at discharge         1.22               (1.16, 1.3)                                     \<0.0001                                                1.30   (1.20, 1.40)   \<0.0001   1.29   (1.19, 1.39)   \<0.0001

Variables used for patient characteristics: age, gender, race (white vs other), medical history of atrial fib/flutter, previous stroke/TIA, CAD/previous MI, carotid stenosis, diabetes, PVD, hypertension, dyslipidemia, smoking, presentation during off hours, NIHSS, and systolic blood pressure. For hospital characteristics: region, academic/teaching hospital, number of beds, rural location, TJC primary stroke center status, annual ischemic stroke volume, and annual tPA volume. CAD indicates coronary artery disease; CI, confidence interval; HbA1c, glycosylated hemoglobin; ICH, intracranial hemorrhage; LOS, length of stay; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; PVD, peripheral vascular disease; TIA, transient ischemic attack; TJC, the joint commission; tPA, tissue plasminogen activator.

Chronic hyperglycemia defined as HbA1C \>6.5%.

To determine whether the nature of the association with hyperglycemia was linear or nonlinear, we also analyzed the relationship of admission blood glucose and HbA1c as continuous variables with the outcomes of in‐hospital mortality and sICH. This analysis was performed separately in those with and without a documented history of diabetes. Because admission blood glucose among patients with documented history of diabetes increased from 40 to 200 mg/dL, it was associated with an increased odds of in‐hospital mortality (OR, 1.07; 95% CI, 1.05 to 1.09; Figure [3](#jah31145-fig-0003){ref-type="fig"}A) and sICH (OR, 1.05; 95% CI, 1.03 to 1.07; Figure [3](#jah31145-fig-0003){ref-type="fig"}B) for every 10 mg/dL increase in blood glucose. Further increases in admission blood glucose above 200 mg/dL were not associated with further increases in rates of in‐patient mortality or sICH. Similar findings were observed in patients without a documented history of diabetes. Because HbA1c among diabetics increased from 6.5% to 8%, it was associated with an increased odds of in‐hospital mortality (OR, 1.19; 95% CI, 1.11 to 1.28; Figure [4](#jah31145-fig-0004){ref-type="fig"}A) and sICH (OR, 1.16; 95% CI, 1.06 to 1.26; Figure [4](#jah31145-fig-0004){ref-type="fig"}B) per 1% increase in HbA1c. Further increases in HbA1c above 8% were not associated with further increases in rates of in‐patient mortality or sICH.

![A, Predicted probability of in‐hospital mortality (adjusted) with 95% confidence intervals; B, predicted probability of symptomatic intracranial hemorrhage (adjusted) with 95% confidence intervals.](JAH3-4-e002193-g003){#jah31145-fig-0003}

![A, Predicted probability of in‐hospital mortality (adjusted) with 95% confidence intervals; B, predicted probability of symptomatic intracranial hemorrhage (adjusted) with 95% confidence intervals. HbA1c indicates glycosylated hemoglobin.](JAH3-4-e002193-g004){#jah31145-fig-0004}

Patients With a Documented History of DM {#jah31145-sec-0010}
----------------------------------------

We performed additional exploratory analyses comparing the influence of acute hyperglycemia on clinical outcomes after thrombolysis in patients with a known history of DM. Patients with a history of diabetes who presented with acute hyperglycemia (blood glucose, \>140 mg/dL) had worse outcomes when compared to those who presented without acute hyperglycemia (Table [5](#jah31145-tbl-0005){ref-type="table-wrap"}). In multivariable analysis, hyperglycemia in patients with a history of diabetes was independently associated with sICH (aOR, 1.39; 95% CI, 1.20 to 1.61), life‐threatening hemorrhage (aOR, 1.68; 95% CI, 1.26 to 2.23), in‐patient mortality (OR, 1.54; 95% CI, 1.35 to 1.75), length of stay \>4 days (aOR, 1.17; 95% CI, 1.10 to 1.25), and inability to ambulate at discharge (aOR, 1.52; 95% CI, 1.40 to 1.66). Finally, we compared clinical outcomes post‐tPA in patients with acute hyperglycemia or elevated HbA1c and who were with versus without a known history of diabetes. Patients with acute hyperglycemia or elevated HbA1c had an increased odds of poor outcomes regardless of a history of known diabetes (Tables [6](#jah31145-tbl-0006){ref-type="table-wrap"} and [7](#jah31145-tbl-0007){ref-type="table-wrap"}, respectively).

###### 

Baseline Patient Characteristics of Acute Stroke Patients and a Documented History of Diabetes (n=15 232) With vs Without Acute Hyperglycemia

  Variable                                Level    Overall (N=15 232)   Acute Hyperglycemia (BG \>140 mg/dL) (N=9363)   No Hyperglycemia (N=5869)   *P* Value                   
  --------------------------------------- -------- -------------------- ----------------------------------------------- --------------------------- ----------- ------- ------- ----------
  Patient characteristics                                                                                                                                                       
  Age                                     Median   15 232               71.0                                            9363                        70.0        5869    72.0    \<0.0001
  25th                                             61.0                                                                 60.0                                    62.0            
  75th                                             80.0                                                                 79.0                                    81.0            
  Gender                                  Female   7585                 49.8                                            4505                        48.1        3080    52.5    \<0.0001
  Onset to treatment time (minutes)       Median   14 580               145.0                                           8956                        146.0       5624    144.0   0.002
  25th                                             113.0                                                                115.0                                   112.0           
  75th                                             176.0                                                                176.5                                   175.0           
  Mean                                             156.2                                                                157.9                                   153.3           
  STD                                              134.2                                                                155.6                                   90.1            
  Medical history                                                                                                                                                               
  Atrial fibrillation/flutter                      3120                 20.5                                            1848                        19.7        1272    21.7    0.004
  Previous stroke/TIA                              4540                 29.8                                            2655                        28.4        1885    32.1    \<0.0001
  CAD/previous MI                                  5220                 34.3                                            3224                        34.4        1996    34.0    0.59
  Carotid stenosis                                 506                  3.3                                             321                         3.4         185     3.2     0.36
  PVD                                              815                  5.4                                             496                         5.3         319     5.4     0.71
  Hypertension                                     13 223               86.8                                            8117                        86.7        5106    87.0    0.59
  Smoker                                           2247                 14.8                                            1356                        14.5        891     15.2    0.25
  Dyslipidemia                                     8093                 53.1                                            4883                        52.15       3210    54.7    0.002
  Heart failure                                    1936                 12.7                                            1185                        12.7        751     12.8    0.80
  NIHSS Score                             Median   15 232               10.0                                            9363                        10.0        5869    10.0    0.003
  25th                                             6.0                                                                  6.0                                     6.0             
  75th                                             17.0                                                                 17.0                                    17.0            
  HbA1C, %                                Median   9954                 7.0                                             6244                        7.6         3710    6.3     \<0.0001
  25th                                             6.2                                                                  6.7                                     5.9             
  75th                                             8.3                                                                  9.1                                     6.9             
  Complications of thrombolytic therapy                                                                                                                                         
  Symptomatic ICH                                  826                  5.5                                             570                         6.1         256     4.4     \<0.0001
  Serious/life‐threatening hemorrhage              188                  1.2                                             137                         1.5         51      0.9     0.001
  Other complication                               595                  3.9                                             395                         4.2         200     3.4     0.01
  In‐hospital mortality                            1349                 8.9                                             951                         10.2        398     6.8     \<0.0001
  LOS \>4 days                                     8168                 55.3                                            5169                        56.9        2999    52.7    \<0.0001
  Unable to ambulate at discharge                  4402                 32.5                                            2952                        35.3        1450    27.9    \<0.0001

BG indicates blood glucose; CAD, coronary artery disease; HbA1c, glycosylated hemoglobin; ICH, intracranial hemorrhage; LOS, length of stay; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; PVD, peripheral vascular disease; TIA, transient ischemic attack.

###### 

Multivariable Model of the Association Between Acute Hyperglycemia and Clinical Outcomes for Patients With vs Without a Documented History of Diabetes

  Outcome                                 Unadjusted Model   Adjusted Model (Patient Characteristics Only)   Fully Adjusted Model (Patient and Hospital Characteristics)                                                                                             
  --------------------------------------- ------------------ ----------------------------------------------- ------------------------------------------------------------- ------ -------------- --------------------------------------------- ------ -------------- ---------------------------------------------
  Complications of thrombolytic therapy                                                                                                                                                                                                                              
  Symptomatic ICH                                                                                            0.13[a](#jah31145-note-0010){ref-type="fn"}                                         1.0[a](#jah31145-note-0010){ref-type="fn"}                          0.9[a](#jah31145-note-0010){ref-type="fn"}
  Diabetic patients                       1.41               (1.23, 1.63)                                    \<0.0001                                                      1.40   (1.22, 1.62)   \<0.0001                                      1.40   (1.21, 1.62)   \<0.0001
  Nondiabetic patients                    1.63               (1.46, 1.81)                                    \<0.0001                                                      1.41   (1.26, 1.56)   \<0.0001                                      1.41   (1.27, 1.57)   \<0.0001
  Serious/life‐threatening hemorrhage                                                                        0.06[a](#jah31145-note-0010){ref-type="fn"}                                         0.29[a](#jah31145-note-0010){ref-type="fn"}                         0.27[a](#jah31145-note-0010){ref-type="fn"}
  Diabetic patients                       1.69               (1.28, 2.25)                                    0.0003                                                        1.66   (1.25, 2.21)   0.0006                                        1.64   (1.23, 2.20)   0.0007
  Nondiabetic patients                    2.43               (1.98, 2.97)                                    \<0.0001                                                      2.01   (1.64, 2.46)   \<0.0001                                      2.02   (1.64, 2.47)   \<0.0001
  Other outcomes                                                                                                                                                                                                                                                     
  In‐hospital mortality                                                                                      \<0.0001[a](#jah31145-note-0010){ref-type="fn"}                                     0.21[a](#jah31145-note-0010){ref-type="fn"}                         0.16[a](#jah31145-note-0010){ref-type="fn"}
  Diabetic patients                       1.56               (1.37, 1.76)                                    \<0.0001                                                      1.58   (1.39, 1.80)   \<0.0001                                      1.55   (1.37, 1.76)   \<0.0001
  Nondiabetic patients                    2.13               (1.96, 2.31)                                    \<0.0001                                                      1.75   (1.61, 1.91)   \<0.0001                                      1.74   (1.60, 1.89)   \<0.0001
  LOS \>4                                                                                                    0.005[a](#jah31145-note-0010){ref-type="fn"}                                        1.0[a](#jah31145-note-0010){ref-type="fn"}                          0.9[a](#jah31145-note-0010){ref-type="fn"}
  Diabetic patients                       1.17               (1.10, 1.25)                                    \<0.0001                                                      1.17   (1.09, 1.25)   \<0.0001                                      1.16   (1.09, 1.24)   \<0.0001
  Nondiabetic patients                    1.31               (1.25, 1.37)                                    \<0.0001                                                      1.17   (1.11, 1.23)   \<0.0001                                      1.17   (1.11, 1.23)   \<0.0001
  Unable to ambulate at discharge                                                                            \<0.0001[a](#jah31145-note-0010){ref-type="fn"}                                     0.61[a](#jah31145-note-0010){ref-type="fn"}                         0.73[a](#jah31145-note-0010){ref-type="fn"}
  Diabetic patients                       1.41               (1.31, 1.53)                                    \<0.0001                                                      1.55   (1.42, 1.69)   \<0.0001                                      1.53   (1.41, 1.67)   \<0.0001
  Nondiabetic patients                    1.78               (1.68, 1.89)                                    \<0.0001                                                      1.51   (1.41, 1.61)   \<0.0001                                      1.50   (1.41, 1.60)   \<0.0001

Variables used for patient characteristics: age, gender, race (white vs other), medical history of atrial fib/flutter, previous stroke/TIA, CAD/previous MI, carotid stenosis, diabetes, PVD, hypertension, dyslipidemia, smoking, presentation during off hours, NIHSS, and systolic blood pressure. For hospital characteristics: region, academic/teaching hospital, number of beds, rural location, TJC primary stroke center status, annual ischemic stroke volume, and annual tPA volume. CAD indicates coronary artery disease; CI, confidence interval; ICH, intracranial hemorrhage; LOS, length of stay; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; PVD, peripheral vascular disease; TIA, transient ischemic attack; TJC, the joint commission; tPA, tissue plasminogen activator.

Interaction *P* value: differences in outcomes between patients with documented history of diabetes vs no diabetes.

###### 

Multivariable Model of the Association Between Chronic Hyperglycemia and Clinical Outcomes for Patients With vs Without a Documented History of Diabetes

  Outcome                                 Unadjusted Model   Adjusted Model (Patient Characteristics Only)   Adjusted Model (Patient and Hospital Characteristics)                                                                                             
  --------------------------------------- ------------------ ----------------------------------------------- ------------------------------------------------------- ------ -------------- --------------------------------------------- ------ -------------- ---------------------------------------------
  Complications of thrombolytic therapy                                                                                                                                                                                                                        
  Symptomatic ICH                                                                                            0.45[a](#jah31145-note-0012){ref-type="fn"}                                   0.87[a](#jah31145-note-0012){ref-type="fn"}                         0.89[a](#jah31145-note-0012){ref-type="fn"}
  Diabetic patients                       1.14               (0.93, 1.39)                                    0.20                                                    1.26   (1.20, 1.55)   0.03                                          1.26   (1.02, 1.55)   0.03
  Nondiabetic patients                    1.27               (1.02, 1.58)                                    0.03                                                    1.23   (0.98, 1.53)   0.07                                          1.24   (0.99, 1.54)   0.06
  Serious/life‐threatening hemorrhage                                                                        0.06[a](#jah31145-note-0012){ref-type="fn"}                                   0.15[a](#jah31145-note-0012){ref-type="fn"}                         0.14[a](#jah31145-note-0012){ref-type="fn"}
  Diabetic patients                       1.04               (0.69, 1.56)                                    0.87                                                    1.11   (0.74, 1.67)   0.60                                          1.10   (0.74, 1.65)   0.63
  Nondiabetic patients                    1.84               (1.20, 2.83)                                    0.005                                                   1.73   (1.13, 2.64)   0.01                                          1.73   (1.13, 2.63)   0.01
  Other outcomes                                                                                                                                                                                                                                               
  In‐hospital mortality                                                                                      0.02[a](#jah31145-note-0012){ref-type="fn"}                                   0.45[a](#jah31145-note-0012){ref-type="fn"}                         0.35[a](#jah31145-note-0012){ref-type="fn"}
  Diabetic patients                       1.11               (0.94, 1.30)                                    0.21                                                    1.31   (1.10, 1.55)   0.002                                         1.29   (1.09, 1.53)   0.003
  Nondiabetic patients                    1.11               (1.24, 1.75)                                    \<0.0001                                                1.45   (1.21, 1.74)   \<0.0001                                      1.46   (1.22, 1.74)   \<0.0001
  LOS \>4                                                                                                    \<0.0001[a](#jah31145-note-0012){ref-type="fn"}                               0.02[a](#jah31145-note-0012){ref-type="fn"}                         0.02[a](#jah31145-note-0012){ref-type="fn"}
  Diabetic patients                       1.05               (0.96, 1.14)                                    0.31                                                    1.13   (1.03, 1.24)   0.09                                          1.13   (1.03, 1.24)   0.01
  Nondiabetic patients                    1.39               (1.25, 1.55)                                    \<0.0001                                                1.35   (1.21, 1.51)   \<0.0001                                      1.35   (1.21, 1.51)   \<0.0001
  Unable to ambulate at discharge                                                                            \<0.0001[a](#jah31145-note-0012){ref-type="fn"}                               0.14[a](#jah31145-note-0012){ref-type="fn"}                         0.12[a](#jah31145-note-0012){ref-type="fn"}
  Diabetic patients                       0.97               (0.89, 1.06)                                    0.57                                                    1.23   (1.12, 1.37)   \<0.0001                                      1.22   (1.11, 1.35)   \<0.0001
  Nondiabetic patients                    1.36               (1.21, 1.53)                                    \<0.0001                                                1.40   (1.23, 1.60)   \<0.0001                                      1.40   (1.23, 1.59)   \<0.0001

Variables used for patient characteristics: age, gender, race (white vs other), medical history of atrial fib/flutter, previous stroke/TIA, CAD/previous MI, carotid stenosis, diabetes, PVD, hypertension, dyslipidemia, smoking, presentation during off hours, NIHSS, and systolic blood pressure. For hospital characteristics: region, academic/teaching hospital, number of beds, rural location, TJC primary stroke center status, annual ischemic stroke volume, and annual tPA volume. CAD indicates coronary artery disease; CI, confidence interval; ICH, intracranial hemorrhage; LOS, length of stay; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio; PVD, peripheral vascular disease; TIA, transient ischemic attack; TJC, the joint commission; tPA, tissue plasminogen activator.

Interaction *P* value: differences in outcomes between patients with documented history of diabetes vs no diabetes.

Discussion {#jah31145-sec-0011}
==========

In this study, we sought to evaluate the association of disorders of glucose metabolism with outcomes of AIS patients treated with intravenous tPA. We characterized patients as having a disorder of glucose metabolism by admission hyperglycemia, a known diagnosis of diabetes, or by use of glycosylated hemoglobin levels. Hyperglycemia, acute or chronic, was associated with increased mortality and worse clinical outcomes in AIS patients treated with tPA. This held true regardless of a previous known diagnosis of diabetes. The relationship was nonlinear, with a plateau observed at glucose levels above 200 mg/dL and HbA1C levels above 8.0%.

Acute hyperglycemia on admission testing is frequently observed in acute stroke. In patients treated with tPA within 3 hours of stroke onset, acute hyperglycemia has been associated with poor outcomes.[12](#jah31145-bib-0012){ref-type="ref"} These observations may be owing, in part, to the possibility of decreased thrombolytic effectiveness of alteplase in the setting of hyperglycemia. A previous study observed that acute, but not chronic, hyperglycemia was associated with lower rates of tPA‐induced recanalization.[20](#jah31145-bib-0020){ref-type="ref"} That study was small and the mean reported HbA1c was 6.3±0.8%. Our study is consistent with, and builds upon, previous studies showing that acute hyperglycemia is associated with fewer favorable outcomes in tPA‐treated patients. However, it is also likely that chronic hyperglycemia may be exerting a role in poor outcomes. Our data also demonstrate that patients with chronic hyperglycemia (as defined by HbA1c \>6.5%) also experienced worse outcomes compared to those with HbA1c levels ≤6.5%. Subset analyses also suggest that the actual values of plasma glucose and HbA1c during admission are more important than a previous documented diagnosis of diabetes per se. These data should raise concern about the risks of poor outcome after thrombolysis for patients with disorders of glucose metabolism, a condition with increasing incidence and prevalence in the United States.[21](#jah31145-bib-0021){ref-type="ref"} It is possible that this risk could be mitigated by better chronic and acute glycemic control. However, because of the nonrandomized design of our study, we were unable to determine whether this increased sICH risk was associated with fewer benefits from tPA. Previous subgroup analyses of tPA randomized, controlled trials show that the effect of tPA is the same in diabetic versus nondiabetic patients.[22](#jah31145-bib-0022){ref-type="ref"} This supports the recommendations of others that thrombolysis can be safely given to diabetic patients.[23](#jah31145-bib-0023){ref-type="ref"}

The exact threshold at which elevated blood glucose levels are associated with elevated risk has not been well established. Previous studies suggested that a blood glucose level of 160 mg/dL or more may be a cutoff for poor outcomes.[20](#jah31145-bib-0020){ref-type="ref"}, [24](#jah31145-bib-0024){ref-type="ref"} One study reported a linear relation between admission glucose and an increase in the odds of sICH (OR 1.75 per 100 mg/dL increase in admission glucose).[5](#jah31145-bib-0005){ref-type="ref"} Admission blood glucose levels were identified as a risk factor for sICH after intravenous tPA in several risk models for sICH post‐tPA.[11](#jah31145-bib-0011){ref-type="ref"}, [25](#jah31145-bib-0025){ref-type="ref"}, [26](#jah31145-bib-0026){ref-type="ref"}, [27](#jah31145-bib-0027){ref-type="ref"}, [28](#jah31145-bib-0028){ref-type="ref"} Although blood glucose is one of the potential modifiable factor in these risk scores, further studies are required to evaluate whether treatment of hyperglycemia reduces risk of sICH post‐tPA. Furthermore, these studies were designed to identify patients at increased risk of sICH and do not conclude benefit or harm of tPA in patients with higher predicted risk. Our study supports the previous observations that worsening of acute or chronic plasma glucose control is associated with increasing mortality, but that the effects are nonlinear and plateau above modest levels of hyperglycemia. Whereas early studies suggested that there may be a role of tight glucose control for reducing MI and coronary heart disease events, randomized, clinical trials have failed to demonstrate measurable benefits for strict acute or chronic glycemic control, and some have suggested increased harm.[29](#jah31145-bib-0029){ref-type="ref"} The potential benefit of strict glucose control with aggressive insulin titration in acute stroke is unclear,[30](#jah31145-bib-0030){ref-type="ref"} and this hypothesis is currently being tested in a large, randomized, clinical trial.[31](#jah31145-bib-0031){ref-type="ref"} To avoid the risk of adverse effects related to hypoglycemia, guidelines recommend to maintain blood glucose in a range of 140 to 180 mg/dL.[32](#jah31145-bib-0032){ref-type="ref"} Whereas our retrospective study suggests that better blood glucose regulation measured at admission is associated with better short‐term clinical outcomes, we did not test or measure any interventions that were given in response to these glucose measurements, and thus these findings require prospective, randomized, clinical trials to evaluate the potential benefits and potential risks of any treatment in this patient population.

The study has important limitations owing to its observational nature and retrospective design. Residual measured and unmeasured confounding may account for some of these findings. Acute and chronic hyperglycemic may be a marker, rather than a mediator, for these adverse outcomes and no cause‐and‐effect relationships should be inferred. Some patients with hyperglycemia on admission, but without diagnosed diabetes, may have had preexisting undiagnosed diabetes. There were missing data for admission glucose and HbA1c, which may have introduced bias into these findings. When compared to patients with missing admission blood glucose, patients with documented admission glucose were similar except for clinically insignificant history of hypertension (73% vs 72%; *P*\<0.001) and being smokers (18% vs 17%; *P*=0.002). When compared to patients with HbA1c not recorded, patients with HbA1c recorded were younger in age (70 vs 73 years; *P*\<0.0001), had more‐frequent documented history of DM (31.6% vs 19.7%; *P*\<0.0001), hypertension (74.5% vs 71.9; *P*\<0.0001), and were more likely to be smokers (19.4% vs 16.8%; *P*\<0.0001). Data on postdischarge outcomes were not available. In addition, data were not available regarding any treatment of hyperglycemia.

In summary, hyperglycemia, whether acute or chronic, is associated with worse clinical outcomes in AIS patients treated with tPA regardless of a previous known diagnosis of diabetes. Admission glucose and HbA1c may help identify patients at increased risk of adverse outcomes, including sICH. Improving glycemic control in the population by primary prevention may help in better outcomes, but needs further evaluation in a prospective, randomized trial.
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